Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026678 | 0.79 | ALDH1A1 (0.36) | ALDH1A1MCL1 | |
| SCHEMBL28976540 | 0.78 | — | — | |
| SCHEMBL19026687 | 0.78 | — | — | |
| SCHEMBL19000015 | 0.78 | EPHX2 (0.36) | ALDH1A1 | |
| SCHEMBL26343606 | 0.76 | MEN1 (0.40) | ALDH1A1MCL1 | |
| SCHEMBL19014082 | 0.75 | — | — | |
| SCHEMBL21535287 | 0.74 | NR1H2 (0.40) | ALDH1A1HSD17B10 | |
| SCHEMBL20670329 | 0.74 | GPR183 (0.35) | ALDH1A1 | |
| SCHEMBL23095576 | 0.72 | — | — | |
| SCHEMBL8957598 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-3497094-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-02-15 | — | — | EP | disclosed |
| EP-3889146-A1 | POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS | Merck Patent GmbH (DE) | 2021-10-06 | — | — | EP | disclosed |
| WO-2018031434-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-15 | — | — | WO | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ALDH1A1 2648/4885HSD17B10 3751/4885MCL1 471/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | ALDH1A1 2465/4885HSD17B10 3851/4885MCL1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.